Resources

LIfT BioSciences ('LIfT' or 'the Company')today announces a grant of €12 million has been awarded from Ireland's Disruptive Technologies Innovation Fund

Members of the Industry Skills Accelerator (ISA) have celebrated a successful year of strengthening the UK’s medicines manufacturing workforce.

We're pleased to announce the appointment of Livija Deban, Chief Scientific Officer at Prokarium, as Chair of its Engineering Biology Advisory Committee (EBAC).

CGT Catapult, an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Jim Faulkner as its new Chairman, effective from 29th July 2025.

In this blog, Martin Turner, Director of Policy and External Affairs at BIA, reflects on the long-anticipated Life Sciences Sector Plan and what it means for scaling UK biotech. This is the first in a series of blogs that will be released in the coming weeks.

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.

The UK government has officially launched its landmark Life Sciences Sector Plan, backed by over £2 billion in public funding and spearheaded by the Department for Science, Innovation and Technology, Business and Trade, and Health and Social Care.

The BioIndustry Association today publishes new data revealing that the UK’s life sciences sector attracted £1.23 billion in venture capital (VC) investment in the first half of 2025, thereby putting it on track to match or surpass 2024’s total.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, shares insights from the BIA's first-of-its-kind funding and investment analysis into UK Deep Biotech.

In this blog, Paul Wann, Business Director Sustainability & Decarbonisation, Emerson, discusses how life sciences companies can reduce emissions and improve sustainability through advanced automation, process control, and efficient management of utilities without compromising the quality or availability of vital therapies.

In this blog, Dr Jonathan Tobin, Partner, Brandon Capital, explores how the UK pension industry can unlock greater economic and societal value by following Australia's example.

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.

The Milner Therapeutics Institute is delighted to be featured in a new report celebrating a decade of partnership and impact between AstraZeneca and the University of Cambridge.

Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Ed Samuel as its Chief Operations Officer (COO).

Pioneer Group and Science Creates today announce a new partnership that will support the next generation of science and technology ventures across the UK and Ireland.

Logical Biological, biospecimen and critical material experts, today announced the launch of a new sister company, Logical Antigen, focused on rapid and customised delivery of high-quality antigens and biologicals, for research and manufacturing of diagnostic products.

After 13 years at the helm of our Association, Steve Bates has tendered his resignation as CEO of the BIA. His last day at the BIA will be Friday, 26 September 2025. We all wish him well in his new role and know he will continue to champion our sector at home and abroad. 

PIR International recently partnered with Sibylla Biotech in appointing Dieter Weinand as Non-Executive Chair.

Construction of Europe’s tallest and most technically sophisticated purpose-built commercial lab building has started on site at Canary Wharf, London.